Scarica l'app Stockscreener
0.795
4.77%
0.0362
Dopo l'orario di chiusura:
.80
0.005
+0.63%
Plus Therapeutics Inc Borsa (PSTV) Ultime notizie
Arch Therapeutics Inc. (ARTH) Product Pipeline Analysis, 2025 Update - GlobeNewswire Inc.
Plus Therapeutics, Inc. shares rise 2.37% premarket after Almirall and Absci expand AI Drug Creation collaboration. - AInvest
Plus Therapeutics Surges 17.46% on Breakthrough FDA Clearance and Strategic Funding Boost – What’s Next for PSTV? - AInvest
Plus Therapeutics shares rise 3.34% premarket after announcing a dose escalation phase 1 study for 186RNL. - AInvest
How does Plus Therapeutics Inc. generate profit in a changing economyHarness the power of proven investment plans - Jammu Links News
What is the dividend policy of Plus Therapeutics Inc. stockCapitalize on fast-moving stock opportunities - Jammu Links News
What is the risk reward ratio of investing in Plus Therapeutics Inc. stockUnlock real-time stock alerts for quick profits - Jammu Links News
What institutional investors are buying Plus Therapeutics Inc. stockConsistent triple-digit returns - Jammu Links News
What makes Plus Therapeutics Inc. stock price move sharplyFree High-Return Strategy Alerts - Jammu Links News
What analysts say about Plus Therapeutics Inc. stockGet timely advice on market trends - Jammu Links News
What drives Plus Therapeutics Inc. stock priceExtraordinary earning power - Jammu Links News
How strong is Plus Therapeutics Inc. company’s balance sheetTop Growth Trend Scanner With High Returns - jammulinksnews.com
Published on: 2025-08-01 22:18:13 - metal.it
Plus Therapeutics (PSTV.O) Surges 16.5% — What's Behind the Sharp Move? - AInvest
Plus Therapeutics’ Innovative Study on Rhenium-186 NanoLiposome for Cancer Metastases - TipRanks
What are analysts’ price targets for Plus Therapeutics Inc. in the next 12 monthsStock Strategy Recommendation From AI Tools - jammulinksnews.com
Plus Therapeutics Provides US Launch Update for its CNSide® Diagnostic - GlobeNewswire
Plus Therapeutics (PSTV) to Introduce CNSide Diagnostics in Texas by August 2025 - GuruFocus
Plus Therapeutics Provides US Launch Update for its CNSide® Diag - GuruFocus
Revolutionary CNS Cancer Test With 92% Accuracy Launches at Major Texas Cancer Centers - Stock Titan
Is Plus Therapeutics Inc. stock overvalued or undervaluedReal Time Watchlist With Proven Results - jammulinksnews.com
Plus Therapeutics (PSTV.O) Plunges 13%: Unpacking the Intraday Shock - AInvest
Institutional Tools Highlight Unusual Flow in Plus Therapeutics Inc.Watchlist for Smart Swing Trading Updated - metal.it
Does Plus Therapeutics Inc. stock perform well during market downturnsBuild wealth steadily with proven investment techniques - jammulinksnews.com
Why is Plus Therapeutics Inc. stock attracting strong analyst attentionAmplify your gains with low-risk picks - Jammu Links News
What catalysts could drive Plus Therapeutics Inc. stock higher in 2025Unlock rapid growth potential in your portfolio - jammulinksnews.com
How volatile is Plus Therapeutics Inc. stock compared to the marketConsistent wealth multiplication - jammulinksnews.com
Published on: 2025-07-27 20:49:15 - jammulinksnews.com
Healthcare Stocks Move in Intrday Session: Gainers and Losers - AInvest
Should I buy Plus Therapeutics Inc. stock before earningsRecord-setting profit potential - jammulinksnews.com
Can Plus Therapeutics Inc. stock recover from recent declineFree Consultation - Jammu Links News
0.24%
3.39%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):